In the past decade, TNF-α inhibitors Humira (AbbVie) and Enbrel (Amgen), as well as Janssen’s IL-12/23 inhibitor Stelara, have been leading the U.S. psoriasis biologics market. However, the recent wave of U.S. approvals for novel psoriasis agents—Celgene’s Otezla (2014), Novartis’s Cosentyx (2015), Eli Lilly’s Taltz (2016), Valeant’s Siliq (2017), and Janssen’s Tremfya (2017)—is anticipated to substantially alter the market landscape. The Psoriasis Emerging Therapy series includes three waves that will track the awareness, trial, and use of Tremfya following its launch in July 2017 for the treatment of psoriasis. In addition, the series will examine physicians’ anticipation of future trends in psoriasis treatment, particularly Tremfya’s uptake, and assess Janssen’s promotional efforts.

Questions Answered:

  • What is the awareness of, familiarity with, and perceptions related to Tremfya among U.S. dermatologists?
  • According to prescribers, to which patients are they prescribing Tremfya, why are they prescribing Tremfya, and how satisfied are they with Tremfya ?
  • How do prescribers and nonprescribers compare across key metrics?
  • How is the trial and adoption of Tremfya tracking compared with other recent product launches in the autoimmune market?

Product Description:

Emerging Therapies is a three-wave series based on primary research data collected at one, six, and twelve months postcommercial launch with U.S. physicians. The research captures physicians’ awareness, perceptions, and use of the launched product, as well as anticipated future trends. Insight is also provided on promotional efforts, prescriber and nonprescriber profiles, and benchmarking against other launched agents.

Table of contents

  • Psoriasis - Emerging Therapies - Tremfya Launch Tracking Wave 1 (US)
    • Key Findings
      • Benchmarking Tremfya Launch Success vs. Other Launched Drugs
        • Key Findings
      • Prescriber and Nonprescriber Profiles
        • Differences Between Tremfya Prescribers and Nonprescribers
        • Differences Between Tremfya Prescriber and Nonprescriber Profiles
      • Tremfya Awareness and Perceptions
        • Unaided and Aided Awareness of Tremfya
          • Unaided Awareness of Approved Drugs for PsO
          • Awareness of Tremfya
          • Awareness of Tremfya's Approval for PsO
          • Awareness of Tremfya's Dosing
          • Estimated Cost of Tremfya
        • Familiarity with Tremfya
          • Sources of Familiarity with Tremfya
            • Initial Reaction to and Interest in Tremfya
              • Initial Reaction to Tremfya After Viewing Product Profile
              • Initial Reaction to Key Attributes of Tremfya After Viewing Product Profile
              • Interest in Learning More About Tremfya
            • Impressions of Tremfya
              • Tremfya Attributes of Which Dermatologists Were Unaware
              • Aspects of Tremfya Profile of Which Dermatologists Were Unaware
              • Perceived Uniqueness of Tremfya
              • Risk-Benefit Ratio of Tremfya
              • Unaided Advantages of Tremfya
              • Unaided Disadvantages of Tremfya
            • Prescriber and Nonprescriber Profiles
              • Differences Between Tremfya Prescriber and Nonprescriber Profiles
          • Tremfya Trial and Use
            • Willingness to Prescribe Tremfya
              • Willingness to Prescribe Tremfya to Psoriasis Patients
              • Impact of Attributes on Willingness to Prescribe Tremfya
            • Number of Patients Currently Receiving Tremfya
              • Biologics and Novel Oral Agents Currently Prescribed to PsO Patients
              • Tremfya Patient Volume
              • Timing of Tremfya Prescription
              • Tremfya Discontinuation Rate
              • Disease Severity of Tremfya-Treated Patients
              • Agents to Which Patients Switched After Discontinuing Tremfya
              • Origination of Patients Treated with Tremfya
              • Agents from Which Patients Were Switched to Tremfya
              • Therapies to Which Tremfya Was Added
              • Reasons for Prescribing Tremfya
              • Number of Patient Inquiries for Tremfya
              • Result of Specific Patient Requests for Tremfya
            • Reasons for Not Yet Prescribing Tremfya
              • Anticipated Use of Tremfya
                • Nonprescriber Timeline for Tremfya Trial
                • Anticipated New Tremfya Users in the Next Month
                • Candidates for Tremfya by PsO Patient Population
                • Candidates for Tremfya by Treatment History
                • Therapies That Tremfya Is Likely to Replace
                • Obstacles to Prescribing Tremfya
                • Anticipated Prescribing of Biologics and Novel Oral Agents for PsO in Next Six Months
              • Tremfya Performance on Key Attributes
                • Overall Satisfaction with Tremfya
                • Ease of Tremfya's Managed Care Approval Process
                • Requirements for Tremfya's Managed Care Approval
                • Mean Total Tremfya Performance on Key Attributes
                • Mean Tremfya Performance on Key Attributes: Prescribers vs. Nonprescribers
                • Tremfya Performance on Key Attributes: Prescribers vs. Nonprescribers
                • Total Tremfya Performance on Key Attributes
            • Effectiveness of Face-to-Face Detailing for Tremfya
              • Frequency and Reach of Tremfya Sales Representatives
                • Most Recent Contact with a Tremfya Representative
                • Frequency of Tremfya Representatives' Visits to Surveyed Dermatologists
              • Satisfaction with Tremfya Sales Representative
                • Performance of Tremfya Sales Representatives
              • Tremfya Message Recall
                • Message Recall During Recent Detail
                • Agents Positioned Against Tremfya During Representative Visit
                • Ideal Tremfya Candidate Suggested by Representative
                • Materials Used During Tremfya Representatives' Visit
            • Methodology
              • Primary Market Research Methodology
              • Physician Demographics
                • Message Recall During Recent Detail
                • Agents Positioned Against Tremfya During Representative Visit
                • Ideal Tremfya Candidate Suggested by Representative
                • Materials Used During Tremfya Representatives' Visit
              • U.S. Region of Practice
              • U.S. State of Practice
              • Practice Setting
              • Practice Location
              • Patients Treated by Disease Severity
              • Percentage of Patients Receiving Prescription Drug Therapy
              • Percentage of Patients Receiving Prescription Drug Therapy by Treatment Category
              • Percentage of Patients Receiving Phototherapy
              • Years in Practice Postresidency
              • Number of PsO Patients Under Physicians' Personal Management
              • Number of PsO Patients Currently Taking Biologics
              • Percentage of PsO Patients Currently Taking Biologics
              • Percentage of Adult PsO Patients
            • Appendix
              • Primary Market Research
                • Message Recall During Recent Detail
                • Agents Positioned Against Tremfya During Representative Visit
                • Ideal Tremfya Candidate Suggested by Representative
                • Materials Used During Tremfya Representatives' Visit
              • Timing of Tremfya Prescription: Mean Number of Patients
              • Tremfya Discontinuation Rate: Mean Number of Patients
              • Tremfya Patients' Disease Severity: Mean Number of Patients
              • Average Time Between Tremfya Initiation and Discontinuation
              • Average Time Between Tremfya Initiation and Discontinuation: Mean Number of Patients
              • Reasons for Discontinuing Tremfya
              • Key Abbreviations

          Author(s): Emily Schriner, MPH

          Emily is an Business Insights Analyst with the Immune and Inflammatory Disorders team at Decision Resources Group. She has authored several content pieces for immune market research reports and keeps the team up-to-date on the immune markets through research on patent life, pricing, and pipeline information.

          Emily earned her Master of Public Health in Nutrition at West Chester University, focusing on research, analysis, and program development. She completed an internship at Nemours Health Network in Wilmington, Delaware where she did nutrition education development and primary research on program evaluation before initially joining DRG as a data analyst on the Research Analytics Team.


          Related Reports

          Psoriasis - Landscape & Forecast - Disease Landscape & Forecast

          The psoriasis therapy market has become increasingly lucrative owing to the growing use of targeted agents. The dominance of the tumor necrosis factor (TNF

          View Details

          Psoriasis - Current Treatment - Detailed, Expanded Analysis Pediatric Psoriasis - Treatment Algorithms - Claims Data Analysis (US)

          Psoriasis is a chronic, inflammatory, autoimmune skin disease that can affect children, adolescents, and adults. Although adult psoriasis and pediatric psoriasis are similar, effective management o...

          View Details

          Psoriasis | Disease Landscape and Forecast | G7 | 2020

          The psoriasis therapy market is becoming increasingly lucrative owing to the growing number of approved biologics. Although TNF-alpha inhibitors continue to dominate the market, their premier posit...

          View Details

          Psoriasis - Geographic Focus: China - Psoriasis|China In-Depth|China

          Psoriasis is an incurable chronic skin condition known to affect more than 8 million people in China. China’s psoriasis market has grown significantly over the last few years owing to the gro...

          View Details